Gludantan

Gludantan
Clinical data
Other namesGludantane; N-Adamantan-1-yl-β-D-glucopyranuronosylamine
Identifiers
  • (2S,3S,4S,5R,6R)-6-(1-adamantylamino)-3,4,5-trihydroxyoxane-2-carboxylic acid
CAS Number
PubChem CID
PubChem SID
ChemSpider
Chemical and physical data
FormulaC16H25NO6
Molar mass327.377 g·mol−1
3D model (JSmol)
  • C1C2CC3CC1CC(C2)(C3)N[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O
  • InChI=1S/C16H25NO6/c18-10-11(19)13(15(21)22)23-14(12(10)20)17-16-4-7-1-8(5-16)3-9(2-7)6-16/h7-14,17-20H,1-6H2,(H,21,22)/t7?,8?,9?,10-,11-,12+,13-,14+,16?/m0/s1
  • Key:CORMWKGBVDLTGH-KIBBNWRDSA-N

Gludantan, or gludantane, is an experimental antiparkinsonian agent of the aminoadamantane group that was never marketed. It has also been described as a "psychotropic" and antidepressant. An analogue of gludantan, N-3,5-dimethylgludantan, is an inactive metabolite of memantine. Gludantan was developed in the Soviet Union and was first described by 1974.

See also

References

  1. ↑ Spasov AA, Khamidova TV, Bugaeva LI, Morozov IS (2000). "Adamantane derivatives: Pharmacological and toxicological properties (review)". Pharmaceutical Chemistry Journal. 34 (1): 1–7. doi:10.1007/BF02524549. ISSN 0091-150X.
  2. 1 2 Kamianov IM, Andrezinia RA (1975). "Ob antiparkinsonicheskoĭ aktivnosti gludantana (predvaritel'noe soobshchenie)" [The antiparkinson activity of gludantan (preliminary report)]. Zhurnal Nevropatologii I Psikhiatrii imeni S.S. Korsakova (in Russian). 75 (6): 910–916. PMID 1217399.
  3. ↑ Klimova NV, Zaitseva NM, Avdyunina NI, Pyatin BM, Morozov IC, Bykov NP, et al. (1990). "Adamantylpyridines and their biological activities". Pharmaceutical Chemistry Journal. 24 (1): 31–35. doi:10.1007/BF00769382. ISSN 0091-150X.
  4. ↑ Jarvis B, Figgitt DP (2003). "Memantine". Drugs & Aging. 20 (6): 465–476, discussion 477–478. doi:10.2165/00002512-200320060-00005. PMID 12710865.
  5. ↑ Matsunaga S, Kishi T, Nomura I, Sakuma K, Okuya M, Ikuta T, et al. (October 2018). "The efficacy and safety of memantine for the treatment of Alzheimer's disease". Expert Opinion on Drug Safety. 17 (10): 1053–1061. doi:10.1080/14740338.2018.1524870. PMID 30222469.
  6. ↑ Zykov MP, Smorodintsev AA, Alexandrova GI, Zlydnikov DM, Golubev DB, Shadrin AS (November 1974). "The present and future of specific prophylaxis of influenza and other acute viral respiratory diseases". The American Review of Respiratory Disease. 110 (5): 537–541. doi:10.1164/arrd.1974.110.5.537 (inactive 12 July 2025). PMID 4611289.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)